KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Net Margin (2016 - 2025)

Historic Net Margin for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to 14.45%.

  • Neogenomics' Net Margin fell 39000.0% to 14.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.0%, marking a year-over-year decrease of 39300.0%. This contributed to the annual value of 11.92% for FY2024, which is 29500.0% up from last year.
  • Neogenomics' Net Margin amounted to 14.45% in Q3 2025, which was down 39000.0% from 24.87% recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Net Margin peaked at 63.61% during Q2 2021, and registered a low of 42.17% during Q1 2022.
  • Its 5-year average for Net Margin is 14.95%, with a median of 16.56% in 2023.
  • In the last 5 years, Neogenomics' Net Margin surged by 714500bps in 2021 and then crashed by -918300bps in 2022.
  • Over the past 5 years, Neogenomics' Net Margin (Quarter) stood at 33.21% in 2021, then soared by 51bps to 16.36% in 2022, then soared by 44bps to 9.21% in 2023, then grew by 3bps to 8.91% in 2024, then plummeted by -62bps to 14.45% in 2025.
  • Its Net Margin was 14.45% in Q3 2025, compared to 24.87% in Q2 2025 and 15.43% in Q1 2025.